Redeye reinforces its positive stance on Guard following a transfer of coverage and a review of the case. We regard the shares as fundamentally undervalued and believe the market fails to recognise the company’s progress in clinical advancements. Our base case of SEK 3.0 per share implies +100% upside potential.

Read more and download the Research Update

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Guard Therapeutics - Overlooked Opportunity

© Modular Finance, source Nordic Press Releases